Actively Recruiting
Effects of Neuromodulation in Laryngeal Dystonia
Led by MGH Institute of Health Professions · Updated on 2026-02-20
25
Participants Needed
1
Research Sites
290 weeks
Total Duration
On this page
Sponsors
M
MGH Institute of Health Professions
Lead Sponsor
N
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Laryngeal dystonia (LD) causes excessive vocal fold abduction (opening) or adduction (closing) leading to decreased voice quality, job prospects, self-worth and quality of life. Individuals with LD often experience episodic breathy voice, decreased ability to sustain vocal fold vibration, frequent pitch breaks and in some cases, vocal tremor. While neuroimaging investigations have uncovered both cortical organization and regional connectivity differences in structures in parietal, primary somatosensory and premotor cortices of those with LD, there remains a lack of understanding regarding how the brains of those with LD function to produce phonation and how these might differ from those without LD. Intervention options for people with LD are limited to general voice therapy techniques and Botulinum Toxin (Botox) injections to the posterior cricoarytenoid (PCA) and/or TA (thyroarytenoid) often bilaterally, to alleviate muscle spasms in the vocal folds. However, the effects of injections are short-lived, uncomfortable, and variable. To address this gap, the aim of this study is to investigate the effectiveness of repetitive transcranial magnetic stimulation (rTMS), a non-invasive neuromodulation technique, in assessing cortical excitability and inhibition of laryngeal musculature. Previous work conducted by the investigator has demonstrated decreased intracortical inhibition in those with adductor laryngeal dystonia (AdLD) compared to healthy controls. The investigators anticipate similar findings in individuals with with other forms of LD, where decreased cortical inhibition will likely be noted in the laryngeal motor cortex. Further, following low frequency (inhibitory) rTMS to the laryngeal motor brain area, it is anticipated that there will be a decrease in overactivation of the TA muscle. To test this hypothesis, a proof-of-concept, randomized study to down-regulate cortical motor signal to laryngeal muscles will be compared to those receiving an equal dose of sham rTMS. Previous research conducted by the investigator found that a single session of the proposed therapy produced positive phonatory changes in individuals with AdLD and justifies exploration in LD.
CONDITIONS
Official Title
Effects of Neuromodulation in Laryngeal Dystonia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age range is 21-85 years
- Diagnosis of Laryngeal Dystonia (LD)
- Able to give informed consent
- Symptoms at worst severity if receiving botulinum toxin injections
- Signed the consent form
You will not qualify if you...
- Other forms of dystonia
- Vocal fold pathology or paralysis
- Essential tremor
- Laryngeal cancer or other neurologic conditions with medications affecting the central nervous system
- History of laryngeal surgery
- Adults lacking the ability to consent or complete assessments and intervention
- Seizure in the last 2 years
- Contraindications to rTMS
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Teresa J Kimberley
Boston, Massachusetts, United States, 02129
Actively Recruiting
Research Team
C
Caitlin Koehler, Lab Manager
CONTACT
T
Teresa J Kimberley, PhD, PT
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here